The investigators are imaging patients with newly diagnosed prostate cancer using a new Positron Emission Tomography (PET) imaging agent (68Ga-NYM032) in order to evaluate the safety and diagnostic performance.
Patient is male and aged >18 years old.
Biopsy proven prostate adenocarcinoma.
Patients electing to undergo Radical Prostatectomy (RP) with Pelvic lymph node dissection (PLND).
ECOG performance status 0-2; expected survival ≥ 6 months.
1. Participants who have previously participated in other interventional clinical trials and are within five physical half-lives, or have received radionuclide agents previously with an interval of less than ten physical half-lives prior to study drug injection.
Single group
68-Ga-NYM032
DrugIV injection
sensitivity and specificity
Assessing the sensitivity and specificity of 68Ga-NYM032 Injection positron emission tomography (PET) on a patient level compared to the histopathology of pelvic lymphatic tissue removed during RP and PLND.
Click on the lead sponsor to view all of their trials.
